Patents Assigned to ALIGOS THERAPEUTICS, INC.
-
Publication number: 20220380770Abstract: The present invention is in the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present invention is in the field of siNA molecules effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.Type: ApplicationFiled: April 9, 2021Publication date: December 1, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
-
Publication number: 20220364096Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: March 5, 2021Publication date: November 17, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Patent number: 11464783Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 3, 2020Date of Patent: October 11, 2022Assignee: Aligos Therapeutics, Inc.Inventors: Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11466274Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.Type: GrantFiled: May 29, 2020Date of Patent: October 11, 2022Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
-
Publication number: 20220177888Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: February 15, 2022Publication date: June 9, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20220143032Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220144811Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220143031Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220009924Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.Type: ApplicationFiled: July 8, 2021Publication date: January 13, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
-
Patent number: 11198699Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 31, 2020Date of Patent: December 14, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Patent number: 11191747Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 1, 2020Date of Patent: December 7, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
-
Publication number: 20210355112Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 25, 2021Publication date: November 18, 2021Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
-
Patent number: 11166976Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.Type: GrantFiled: September 11, 2020Date of Patent: November 9, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
-
Publication number: 20210317457Abstract: The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are antisense oligonucleotide (ASO) molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present disclosure provides specific ASOs that are effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
-
Patent number: 11136321Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 27, 2020Date of Patent: October 5, 2021Assignee: Aligos Therapeutics, Inc.Inventor: Sandrine Vendeville
-
Patent number: 11091467Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: GrantFiled: May 7, 2020Date of Patent: August 17, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
-
Patent number: 11033556Abstract: Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing.Type: GrantFiled: February 12, 2020Date of Patent: June 15, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, David Bernard Smith
-
Publication number: 20200385735Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.Type: ApplicationFiled: May 29, 2020Publication date: December 10, 2020Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
-
Publication number: 20200354345Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 7, 2020Publication date: November 12, 2020Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval